Inclusion Criteria:

- Pts confirmed GBM, GS, AA, AO & AOA w recurrent disease following standard therapy
consisting of at least external beam XRT & temo chemo

- Pts not had tumor biopsy <1 week/surgical resection <2 weeks prior to starting study
drug

- Pts should be on non-increasing dose of steroids >7 days prior to obtaining baseline
Gd-MRI of brain

- Age >18yrs

- KPS >70

- ANC >1.5 x 10 9/L

- Hgb >9 g/dL

- Platelets >100 x 10 9/L

- AST/SGOT & ALT/SGPT <2.5 x ULN

- Serum bilirubin <1.5 x ULN

- Serum CA <12 mg/dL

- Serum creatinine <1.5 x ULN/measured 24-hr CrCl>50mL/min/1.73m^2

- Pt has ability to understand & provide signed informed consent that fulfills IRB
guidelines

Exclusion Criteria:

- Prior gr3/>toxicity/failure to CPT-11 therapy

- Prior Sunitinib malate therapy

- Concurrent administration of EIAEDs

- Major surgery <2 weeks of enrollment

- History of impaired cardiac function

- Other clinically significant cardiac diseases

- Uncontrolled diabetes

- Active/uncontrolled infection requiring intravenous antibiotics

- Impairment of GI function/GI disease that may significantly alter absorption of
Sunitinib malate Sutent

- Acute/chronic liver/renal disease

- Cerebrovascular accident/transient ischemic attack <6mths of study enrollment

- Pulmonary embolism <6mths of study enrollment

- Pre-existing thyroid abnormality w thyroid function that can not be maintained in
normal range w medication

- Pts taking warfarin sodium

- Pts have received chemo ≤4wks to starting study drug unless they have fully recovered
from all anticipated side effects of such therapy

- Pts have received immunotherapy ≤2wks to starting study drug/have not recovered from
side effects of such therapy

- Pts have received investigational drugs ≤2wks to starting study drug unless they have
fully recovered from all anticipated side effects of such therapy

- Pts have received XRT ≤4wks to starting study drug unless they have fully recovered
from all anticipated side effects of such therapy

- Pts have undergone major non-CNS surgery ≤2wks to starting study drug/pts who have
not recovered from side effects of such therapy

- Cardiac pacemaker

- Ferromagnetic metal implants other than those approved as safe for use in MR scanners

- Claustrophobia

- Obesity

- Female pts who are pregnant/breast feeding/adults of reproductive potential not
employing effective method of birth control

- Known diagnosis of HIV

- History of another primary malignancy that is currently clinically
significant/currently requiring active intervention

- Pts unwilling to/unable to comply w protocol

- Existing intra-tumoral hemorrhage

- Concurrent participation in another clinical trial except for supportive
care/non-treatment trials

- Other severe acute/chronic medical/psychiatric condition/lab abnormality that may
increase risk associated w study participation/study drug administration/ may
interfere w interpretation of study results, & in judgment of investigator would make
subject inappropriate for entry into this study